0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessIn patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).
Luciano J. Costa, Nizar J. Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gastón Caeiro, Alain Kentos, Vânia Hungria, Donna Reece, Ting Niu, Anne K. Mylin, Charlotte T. Hansen, Raphael Teipel, Britta Besemer, Meletios A Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kım, Chang Ki Min, Paul A. F. Geerts, Elena van Leeuwen-Segarceanu, Agata Tyczyńska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodríguez‐Otero, Joaquín Martínez‐López, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Deborah Briseno-Toomey, Lisa O’Rourke, Ingrid Maria Cecilia Rubin, Diego Vieyra, Lijuan Kang, María‐Victoria Mateos (2025). Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. , 394(8), DOI: https://doi.org/10.1056/nejmoa2514663.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2025
Authors
44
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1056/nejmoa2514663
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
